The Western Europe Healthcare Market Outlook for 2026

2025 has presented significant challenges for healthcare companies in Europe, including U.S. tariffs on healthcare products and the negative implications of increasing pricing pressures in the U.S. for pharmaceuticals. Healthcare companies in Europe also face higher regulatory complexity, as regional and national authorities in the region have introduced various pieces of legislation in recent years targeting the healthcare sector.

As macroeconomic headwinds in Europe continue, national governments have become more determined to negotiate lower prices for healthcare products. All these factors require healthcare companies to take a more strategic and agile approach in 2026.

Join us on Wednesday, July 30, as our experts examine:

• The potential effects of Trump tariffs on healthcare markets in Europe
• The potential effects of the 12 May decree to lower drug prices in the U.S.
• The evolving regulatory landscape in Western Europe
• Existing pricing pressures in key markets
• Strategies to navigate challenges and increase profitability in Western Europe